scholarly article | Q13442814 |
P50 | author | Jerry Avorn | Q6183214 |
Sebastian Schneeweiss | Q60162120 | ||
Michael E Weinblatt | Q88922582 | ||
Jeffrey N Katz | Q89419301 | ||
Daniel H Solomon | Q91503755 | ||
P2093 | author name string | Raisa Levin | |
Soko Setoguchi | |||
P2860 | cites work | Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 |
Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease | Q45151895 | ||
The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. | Q52373114 | ||
P433 | issue | 12 | |
P921 | main subject | circulatory system | Q11068 |
rheumatoid arthritis | Q187255 | ||
hospitalization | Q3140971 | ||
P304 | page(s) | 3790-3798 | |
P577 | publication date | 2006-12-01 | |
P1433 | published in | Arthritis & Rheumatology | Q4797636 |
P1476 | title | Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis | |
P478 | volume | 54 |
Q42533885 | 6-Mercaptopurine, monocytes, and atherosclerosis |
Q36434758 | A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1 |
Q36434813 | A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. |
Q34154483 | Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission |
Q64123686 | An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches |
Q55008598 | Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated by Serum Amyloid A. |
Q37169541 | Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. |
Q43578147 | Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study |
Q36253671 | Atherosclerosis and rheumatoid arthritis: more than a simple association |
Q38365624 | Atherosclerotic vascular disease in the autoimmune rheumatologic patient |
Q56243555 | Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study |
Q85069915 | Biologics and cardiovascular risk |
Q90666678 | Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate |
Q33713206 | Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature |
Q33943374 | Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment |
Q36757060 | Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study |
Q37859676 | Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity |
Q34081242 | Cardiovascular involvement in autoimmune diseases |
Q37808570 | Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications |
Q38260198 | Cardiovascular risk and the use of biologic agents in rheumatoid arthritis |
Q26738461 | Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach |
Q36361147 | Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs |
Q37142052 | Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs |
Q37026106 | Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? |
Q37300823 | Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis |
Q39829013 | Comorbid conditions are associated with healthcare utilization, medical charges and mortality of patients with rheumatoid arthritis |
Q40961450 | Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis |
Q80093117 | Does treatment with DMARDs decrease the risk of cardiovascular disease in patients with RA? |
Q36241707 | Effects of Methotrexate on Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis. |
Q37883018 | Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. |
Q99638169 | Ethnic Disparities in Atherosclerotic Cardiovascular Disease Incidence and Prevalence Among Rheumatoid Arthritis Patients in the United States: a Systematic Review |
Q34238357 | Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity |
Q28540791 | Harmful effects of the azathioprine metabolite 6-mercaptopurine in vascular cells: induction of mineralization |
Q40212689 | High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database. |
Q37245192 | Infliximab improves vascular stiffness in patients with rheumatoid arthritis |
Q34081364 | Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study |
Q34019267 | Initiation of rheumatoid arthritis treatments and the risk of serious infections |
Q36191250 | Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases |
Q37398563 | Interpreting studies of cardiovascular mortality in rheumatoid arthritis: the importance of timing |
Q37704498 | Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. |
Q37975943 | Managing cardiovascular risk in patients with chronic inflammatory diseases. |
Q26998660 | Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation |
Q46546902 | Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques. |
Q35243557 | No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease |
Q38098935 | Novel risk factors for cardiovascular disease in rheumatoid arthritis |
Q34773536 | Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions |
Q36951050 | Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors |
Q44051899 | Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease |
Q28709376 | Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis |
Q31005025 | Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data |
Q40386790 | Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. |
Q37632485 | Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review |
Q40850003 | Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis |
Q38794852 | Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity? |
Q99581776 | Rheumatoid Arthritis is Not Associated with Increased Inpatient Mortality in Patients Admitted for Acute Coronary Syndrome |
Q82076745 | Rheumatoid arthritis and cardiovascular disease |
Q37310447 | Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings |
Q33648507 | Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis |
Q33714074 | Risk of stroke in patients with rheumatism: a nationwide longitudinal population-based study. |
Q41176187 | Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides |
Q59352564 | Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314 |
Q38797087 | Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. |
Q36968832 | Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus |
Q35377706 | Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease |
Q37894193 | TNF alpha antagonist therapy and safety monitoring |
Q92885360 | Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection |
Q33892790 | The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study |
Q50233845 | Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk |
Q37230796 | Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease |
Q44293608 | Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis |
Q37808889 | Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review |
Q42575985 | Use of administrative claims data for comparative effectiveness research of rheumatoid arthritis treatments |
Q35754240 | Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. |
Q35135179 | Validity of myocardial infarction diagnoses in administrative databases: a systematic review |
Q35954625 | What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. |
Q84815164 | [Cardiovascular comorbidity and its risk factors in rheumatoid arthritis] |
Search more.